Discontinued — last reported Q2 '25
Business Segments · Accounts Receivable, Credit Loss Expense (Reversal)
U.S. Pharmaceutical — Accounts Receivable, Credit Loss Expense (Reversal)
McKesson U.S. Pharmaceutical — Accounts Receivable, Credit Loss Expense (Reversal) decreased by 6.9% to $189.00M in Q2 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ3 2023
Last reportedQ2 2025
Rolls up toProvision for Credit Losses
How to read this metric
A reversal or low expense indicates strong customer credit quality and effective accounts receivable management.
Detailed definition
Reflects the net impact of provisions for bad debt or the reversal of previously recorded credit losses within the U.S....
Peer comparison
Standard metric for evaluating credit risk management in B2B distribution industries.
Metric ID:
mck_segment_u_s_pharmaceutical_accounts_receivable_credit_loss_expense_reversalHistorical Data
4 periods
| Q3 '23 | Q4 '23 | Q3 '24 | Q2 '25 | |
|---|---|---|---|---|
| Value | $210.00M | $515.00M | $203.00M | $189.00M |
| QoQ Change | — | +145.2% | -60.6% | -6.9% |
| YoY Change | — | — | -3.3% | — |
Range$189.00M – $515.00M
Avg YoY Growth-3.3%
Median YoY Growth-3.3%
Current Streak2 quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — accounts receivable, credit loss expense (reversal)?
- McKesson (MCK) reported u.s. pharmaceutical — accounts receivable, credit loss expense (reversal) of $189.00M in Q2 2025.
- What does u.s. pharmaceutical — accounts receivable, credit loss expense (reversal) mean?
- The net cost or recovery related to uncollectible customer payments in the segment.